Primary Biliary Cirrhosis. Therapeutic Advances.

Frank Czul, Adam Peyton, Cynthia Levy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure. Because liver transplantation remains the only curative option for PBC, the goals of treatment are to slow the rate of progression, to alleviate related symptoms, and to prevent complications. Ursodeoxycholic acid is the only US Food and Drug Administration-approved medical treatment of PBC. Several agents are undergoing evaluation as monotherapy or as an adjuvant to ursodeoxycholic acid. This review summarizes current therapeutic advances in the care of patients with PBC.

Original languageEnglish
Pages (from-to)229-242
Number of pages14
JournalClinics in Liver Disease
Volume17
Issue number2
DOIs
StatePublished - May 1 2013

Fingerprint

Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Therapeutics
Liver Failure
United States Food and Drug Administration
Bile Ducts
Liver Transplantation
Liver Diseases
Patient Care
Fibrosis

Keywords

  • 6α-Ethyl-chenodeoxycholic acid
  • Fibrates
  • Primary biliary cirrhosis
  • Therapeutics
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology

Cite this

Primary Biliary Cirrhosis. Therapeutic Advances. / Czul, Frank; Peyton, Adam; Levy, Cynthia.

In: Clinics in Liver Disease, Vol. 17, No. 2, 01.05.2013, p. 229-242.

Research output: Contribution to journalArticle

Czul, Frank ; Peyton, Adam ; Levy, Cynthia. / Primary Biliary Cirrhosis. Therapeutic Advances. In: Clinics in Liver Disease. 2013 ; Vol. 17, No. 2. pp. 229-242.
@article{60676dfcff55438485bb574b0fbc67f0,
title = "Primary Biliary Cirrhosis. Therapeutic Advances.",
abstract = "Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure. Because liver transplantation remains the only curative option for PBC, the goals of treatment are to slow the rate of progression, to alleviate related symptoms, and to prevent complications. Ursodeoxycholic acid is the only US Food and Drug Administration-approved medical treatment of PBC. Several agents are undergoing evaluation as monotherapy or as an adjuvant to ursodeoxycholic acid. This review summarizes current therapeutic advances in the care of patients with PBC.",
keywords = "6α-Ethyl-chenodeoxycholic acid, Fibrates, Primary biliary cirrhosis, Therapeutics, Ursodeoxycholic acid",
author = "Frank Czul and Adam Peyton and Cynthia Levy",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.cld.2012.12.003",
language = "English",
volume = "17",
pages = "229--242",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Primary Biliary Cirrhosis. Therapeutic Advances.

AU - Czul, Frank

AU - Peyton, Adam

AU - Levy, Cynthia

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure. Because liver transplantation remains the only curative option for PBC, the goals of treatment are to slow the rate of progression, to alleviate related symptoms, and to prevent complications. Ursodeoxycholic acid is the only US Food and Drug Administration-approved medical treatment of PBC. Several agents are undergoing evaluation as monotherapy or as an adjuvant to ursodeoxycholic acid. This review summarizes current therapeutic advances in the care of patients with PBC.

AB - Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease characterized by destruction of the interlobular bile ducts, which, if untreated, leads to fibrosis, biliary cirrhosis, and liver failure. Because liver transplantation remains the only curative option for PBC, the goals of treatment are to slow the rate of progression, to alleviate related symptoms, and to prevent complications. Ursodeoxycholic acid is the only US Food and Drug Administration-approved medical treatment of PBC. Several agents are undergoing evaluation as monotherapy or as an adjuvant to ursodeoxycholic acid. This review summarizes current therapeutic advances in the care of patients with PBC.

KW - 6α-Ethyl-chenodeoxycholic acid

KW - Fibrates

KW - Primary biliary cirrhosis

KW - Therapeutics

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84875625949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875625949&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2012.12.003

DO - 10.1016/j.cld.2012.12.003

M3 - Article

VL - 17

SP - 229

EP - 242

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 2

ER -